A Combined Synthetic-Fibrin Scaffold Supports Growth and Cardiomyogenic Commitment of Human Placental Derived Stem Cells by Lisi, Antonella et al.
A Combined Synthetic-Fibrin Scaffold Supports Growth
and Cardiomyogenic Commitment of Human Placental
Derived Stem Cells
Antonella Lisi
1, Enrica Briganti
2., Mario Ledda
1., Paola Losi
2., Settimio Grimaldi
1, Rodolfo Marchese
3,
Giorgio Soldani
2*
1Institute of Translational Pharmacology, National Research Council (C.N.R.), Roma, Italy, 2Institute of Clinical Physiology, National Research Council (C.N.R.), Massa, Italy,
3Research Center, S. Peter Hospital FBF, Rome, Italy
Abstract
Aims: A potential therapy for myocardial infarction is to deliver isolated stem cells to the infarcted site. A key issue with this
therapy is to have at one’s disposal a suitable cell delivery system which, besides being able to support cell proliferation and
differentiation, may also provide handling and elastic properties which do not affect cardiac contractile function. In this
study an elastic scaffold, obtained combining a poly(ether)urethane-polydimethylsiloxane (PEtU-PDMS) semi-interpene-
trating polymeric network (s-IPN) with fibrin, was used as a substrate for in vitro studies of human amniotic mesenchymal
stromal cells (hAMSC) growth and differentiation.
Methodology/Principal Findings: After hAMSC seeding on the fibrin side of the scaffold, cell metabolic activity and
proliferation were evaluated by WST-1 and bromodeoxyuridine assays. Morphological changes and mRNAs expression for
cardiac differentiation markers in the hAMSCs were examined using immunofluorescence and RT-PCR analysis. The
beginning of cardiomyogenic commitment of hAMSCs grown on the scaffold was induced, for the first time in this cell
population, by a nitric oxide (NO) treatment. Following NO treatment hAMSCs show morphological changes, an increase of
the messenger cardiac differentiation markers [troponin I (TnI) and NK2 transcription factor related locus 5 (Nkx2.5)] and a
modulation of the endothelial markers [vascular endothelial growth factor (VEGF) and kinase insert domain receptor (KDR)].
Conclusions/Significance: The results of this study suggest that the s-IPN PEtU-PDMS/fibrin combined scaffold allows a
better proliferation and metabolic activity of hAMSCs cultured up to 14 days, compared to the ones grown on plastic dishes.
In addition, the combined scaffold sustains the beginning of hAMSCs differentiation process towards a cardiomyogenic
lineage.
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Introduction
Myocardial infarction (MI) is the most common cause of death
and disability worldwide. Extensive loss of cardiomyocytes,
substituted by scarred tissue, is the key pathological mechanism
leading to left ventricle (LV) dilation and dysfunction and finally to
post infarction heart failure. The use of exogenous cells to replace
lost cardiomyocytes is a potential therapy to prevent cardiac
remodeling and to improve LV function after MI, as it has been
demonstrated in animal models and in clinical trials by
transplanting mesenchymal stem cells (MSCs) into the infarcted
area [1–5].
However, the conventional cell delivery by injection into the
infarcted area is often limited by a low cell engraftment [6,7] and
an inhomogeneous cell delivery, leading to a spotty distribution of
cells within the myocardial scar [4].
The implantation of cellularized scaffolds directly onto the
infarcted area potentially overcomes the significant loss of cells
from the site of injury following transplantation [8,9]. Simpson
and colleagues [10] demonstrated that the delivery of human
MSCs by a collagen hydrogel, directly applied on the epicardial
surface of the infarction, reduces myocardial remodeling. Liu et al.
[11] showed that a fibrin patch seeded with MSCs surgically
implanted onto necrotic areas improved LV contraction, and
prevented LV dilation and heart failure. Recently, Xiong and
colleagues [12] demonstrated that the transplantation of vascular
cells derived from human embryonic stem cells by a fibrin 3D
porous scaffold, resulted in a significant engraftment and LV
functional improvement.
However, the poor mechanical properties of these biopolymer-
based cell delivery systems may restrict their field of use. For
cardiac regeneration it will be necessary to develop a cell delivery
system which, besides being able to support cell proliferation, may
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cardiac contractile function. To this end we developed a combined
scaffold, constituted by a fibrin layer able to sustain cell growth
and differentiation, and by a microporous synthetic layer made of
poly(ether)urethane-polydimethylsiloxane (PEtU-PDMS) semi-in-
terpenetrating polymeric network (s-IPN) able to mechanically
reinforce the fibrin layer providing, at the same time, suitable
elastic properties to the whole scaffold.
Regarding the stem cells that can be used for cardiac
regeneration, MSCs seem the most appropriate cell type to use,
since due to their multilineage potential they can differentiate into
a variety of cell types including cardiomyocytes and vascular
endothelial cells [13,14]. In terms of stem cell supply, the term
placenta constitutes a very reliable rich source of fetal MSCs that
can be kept even after a consistent number of passages (5–10).
These cells, named human amniotic mesenchymal stromal cells
(hAMSCs), are capable of differentiating into multiple different
cell types and have immunological properties that suggest their use
in an allogenic transplantation setting. In this respect, it is
important to remember that placenta has a fundamental role in
maintaining fetomaternal tolerance and, therefore, the immuno-
modulatory properties of these cells have been investigated with
the aim of exploring their applicability in cell therapy-based
treatments. The low immunogenic properties of hAMSCs are
partially explained by their low or limited levels of HLA-ABC, and
by the fact that they do not express HLA-DR and co-stimulatory
molecules [15–18]. Their recovery do not involve any invasive
procedures for the donor and their use does not create any ethical
issue. In addition, the fact that placenta is generally discarded after
birth and is available in large supplies, makes hAMSCs an
excellent candidate for their eventual use in cell therapy
approaches [15,19,20].
Based on these considerations we investigated the feasibility of
using hAMSCs seeded on the fibrin side of the combined s-IPN
PEtU-PDMS/fibrin scaffold for a potential delivery of these cells
to necrotic myocardial areas. In this study we report, for the first
time concerning the hAMSCs population, the results about their
growth and the beginning of cardiomyogenic commitment,
following nitric oxide (NO) treatment, on this scaffold.
Results
Light microscopy
The stereo-microscopical observation of the s-IPN PEtU-
PDMS/fibrin combined scaffold cross-section, after Ponceau red
staining, showed the presence of a homogeneous fibrin layer
covering the synthetic surface. The fibrin layer exhibited a deep
and even red coloration; on the contrary the s-IPN PEtU-PDMS
layer does not uptake the dye and appears white. The thicknesses
of the fibrin and the s-IPN PEtU-PDMS layers, evaluated by
images analysis, were about 750 mm and 900 mm respectively
(Fig. 1).
Scanning electron microscopy (SEM)
SEM microphotographs of the fibrin side of the s-IPN PEtU-
PDMS/fibrin combined scaffold showed a fibrin network
composed of randomly oriented nanofibers that completely covers
the underlying s-IPN PEtU-PDMS material (Fig. 2). The average
fibers diameters, measured by software Axiovision Rel. 4.6 (Carl
Zeiss), was about 130 nm.
Metabolic activity of hAMSC grown on fibrin combined
scaffold or Petri dish and differentiated with NO
hAMSCs treated (NO curve) or not treated (CTR curves) with
SNAP, were cultured on the s-IPN PEtU-PDMS/fibrin combined
scaffold and plastic Petri dishes for up to 14 days. hAMSCs grown
on the scaffold surface showed a significant increase of the
metabolic activity compared to the cells cultured in the Petri dish,
as assessed by WST-1 assay at different time points. We also found
a low metabolism in these cells treated with the differentiating
agent NO (Fig. 3A) by the WST-1. These results highlight a better
cell-friendly environment of this scaffold compared to Petri dishes.
Figure 1. Stereo-microphotographs of the cross-section of the
fibrin-based scaffold after Ponceau red staining (O.M. 306). a)
the fibrin layer shows a thickness of approximately 750 mm, b) the s-IPN
PEtU-PDMS layer shows a thickness of approximately 900 mm. The two
layers appear firmly attached.
doi:10.1371/journal.pone.0034284.g001
Figure 2. SEM-microphotographs of the fibrin side of the
scaffold. The fibrin nanofibers appear randomly oriented and
completely covering the underlying s-IPN PEtU-PDMS material (O.M.
10006).
doi:10.1371/journal.pone.0034284.g002
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scaffold or Petri dish and differentiated with NO
Exponentially growing human amniotic mesenchymal stromal
cells were grown on the s-IPN PEtU-PDMS/fibrin combined
scaffold and plastic Petri dish up to 14 days. These cells revealed a
higher metabolism corresponding to a higher proliferation rate as
assessed by 5-bromo-29-deoxy-uridine (BrdU) assay. Accordingly
hAMSC cultured on the fibrin combined scaffold (CTR scaffold)
showed a higher and more rapid proliferation rate up to 5 days, in
comparison with the CTR Petri dish. After that the proliferation
rate slowly decrease up to reach the same value of the CTR Petri
dish at 10–14 days (Fig. 3B). Moreover, their differentiation by
exposure to NO, as expected, showed a decrease in cell
proliferation rate up to 5 days and an increase up to 14 days, in
comparison with CTR scaffold. From the above results it is
possible to state that the proliferation rate of hAMSCs grown on
the scaffold is better compared to the one of the cells grown on
Petri dishes, confirming the biocompatibility of this scaffold.
mRNA expression of hAMSC grown on fibrin combined
scaffold and differentiated with NO
The differentiation status of the NO-exposed cells was further
assessed by examining mRNA levels for cardiac and vascular
specific genes. NO treatment of hAMSCs grown on the s-IPN
PEtU-PDMS/fibrin combined scaffold showed a significant
increase in the expression of cardiac markers, and an opposite
trend in the expression of vascular markers during the later part of
the experiment (Fig. 4). RT-PCR analysis revealed a statistically
significant increase at 7, 9 and 14 days in the relative Troponin I
(TnI) expression and at 9 and 14 days for Nkx2.5 expression
compared to the control cells (Fig. 4 A,B). The vascular
differentiation markers such as Vascular endothelial growth factor
Figure 3. WST-1 and BrdU incorporation assays. (A) The WST-1 assay performed on hAMSCs cultured on the fibrin-based scaffold (Control
Scaffold=CTR Scaffold) showed a higher metabolic activity than hAMSCs cultured on Petri dishes (Control Petri dish=CTR Petri dish). The
differentiated cells cultured on the fibrin-based scaffold treated with NO (NO Scaffold) showed a decrease in metabolic activity. (B) The BrdU pulse-
labelling time-course performed on hAMSCs cultured on CTR Scaffold showed a higher and more rapid proliferation rate up to 5 days, in comparison
with cells cultured on CTR Petri dish. After that the cell proliferation rate on CTR scaffold slowly decrease up to reach the same value of the CTR Petri
dish at 10–14 days. Cells treated with NO (NO Scaffold) decrease their proliferation rate from days 2 up to 5, while from days 6 up to 14 showed a
higher proliferation rate, in comparison with the control cells.
doi:10.1371/journal.pone.0034284.g003
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showed a modulation trend with an early increase in their
expression. VEGF and KDR mRNAs remained high up to 7 days
and then slowly decreased at 9 and 14 days compared to control
cells (Fig. 4 C,D). It is important to note that from the fourth to the
seventh day of the experiment a greater level of both cardiac and
vascular differentiation markers were found in the NO treated
cells. The NO treatment is able to induce in hAMSCs grown on
the scaffold a modulation of both cardiac and vascular mRNA
markers.
Vimentin and actin expression and distribution of hAMSC
grown on fibrin combined scaffold and differentiate with
NO
Vimentin (57 kDa) is an ubiquitous intermediate filament
protein expressed in a wide variety of MSCs types and detected
at a high level in immature stem cells and at a low level in fully
differentiated stem cells. By indirect immunofluorescence analysis
we observed a decrease in the vimentin protein expression in the
hAMSCs growing on the s-IPN PEtU-PDMS/fibrin combined
scaffold treated with NO (Fig. 5 E,F,G) compared to control cells
(CTR) (Fig. 5 A,B,C,D). Densitogram analysis revealed a statistical
significant reduction of vimentin fluorescence intensity at 4, 7 and
14 days of culture, while the hAMSCs were differentiating
compared to the intensity recorded by the control cells (Fig. 6).
We also investigated the effect of NO treatment on cytoskeleton
organization in hAMSCs growing up on the s-IPN PEtU-PDMS/
fibrin combined scaffold. The fluorescence analysis of filamentous
actin (F-actin) stained by Phalloidin showed that the actin filament
organization on control cells was homogenously distributed on the
full cellular body (Fig. 5 H,I,L,M) and maintained for all 14 days.
Instead in the differentiating hAMSCs the actin network was
highly concentrated around the periphery of the cell and formed
unidirectional long streaked myofibrils grouped in large bundles
(Fig. 5 N,O,P). The actin reorganization and the vimentin
reduction suggest a beginning of cardiomyogenic commitment
through NO treatment in hAMSCs.
Discussion
Reconstituting infarcted tissue with cells capable of performing
the functions of the heart or providing beneficial trophic factors for
native cells is an attractive solution for myocardial repair [23–25].
Figure 4. Quantitative real-time polymerase chain reaction in cardiac and vascular differentiation markers. A statistical significant
increase in relative Nkx2.5, and TnI mRNA levels in NO treated cells (NO) compared to control cells (CTR) at 7, 9 and 14 days was shown (A, B). A high
level of VEGF expression at 4 and 7 days followed by a time-related reduction at 9 and 14 days in KDR mRNA levels in NO treated cells (NO) compared
to control cells (CTR) was also detected (C, D). *P,0.05.
doi:10.1371/journal.pone.0034284.g004
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be delivered efficiently by a cell delivery system. In this study, we
tested the feasibility of a tissue-engineered approach for the
potential delivery of hAMSCs to an infarcted myocardium. In
particular, for the first time, hAMSCs were grown on a s-IPN
PEtU-PDMS/fibrin combined scaffold and treated with NO as
differentiating agent towards a cardiomyogenic lineage.
In this respect it is worth to mention that several tissue
engineering approaches have already been undertaken for cardiac
cell replacement therapy [26–34]. These include the use of
biomaterial-based cellular patches to restore myocardial function.
Biomaterials that have been investigated as potential scaffolds for
cardiovascular tissue engineering applications can be broadly
classified into categories of synthetic or naturally derived
substances. Unfortunately, none of these meet the characteristics
of an ideal scaffold. Common scaffold materials, ranging from
biological materials such as decellularized xenogenic or allogenic
matrices [35,36], fibrin and collagen [37,38] to synthetic polymers
such as polyglycolic acid (PGA), polylactic acid (PLA), polyhy-
droxybutrate (PHB) as well as co-polymers of PLA acid and PGA
[39,40] meet some but not all of the requirements for an ideal
scaffold material.
Among the biological materials, fibrin gel, which is a naturally
occurring biodegradable matrix, has many inherent properties
that make it an ideal natural biological scaffold for tissue
engineering applications. Fibrin-based biomaterials are biocom-
patible and biodegradable and have high affinity to various
biological surfaces [41]. Being a naturally occurring physiological
scaffold, it supports angiogenesis and tissue repair [42].
The ability of fibrin to stimulate and support the growth of new
blood vessels is well documented and plays an important role in re-
establishing blood supply to ischemic tissues [43,44]. In addition,
fibrin naturally contains sites for cellular binding, and it has been
shown to have excellent cell seeding effects and good tissue
development [45]. However, the most significant drawback of
fibrin gels is that they are structurally too weak to withstand
dynamic physiological environments in vivo [46].
Therefore, the very poor mechanical properties of fibrin gel
encourages researchers to combine fibrin with synthetic materials
in order to obtain scaffolds with appropriate tensile strength,
elasticity and handling for applications in the ischemic heart [47].
Figure 5. Immunofluorescence analyses of vimentin and actin filaments expression of hAMSCs cultured on the fibrin-based
scaffold. Examination of vimentin immunostaining (green hue) and marking of nuclei with Hoechst (blue hue) in the hAMSCs grown on the fibrin–
based scaffold whether treated (Differentiated cells; E,F,G) or not (Control cells; A,B,C,D) with NO at 1, 4, 7 and 14 days of culture (O.M. 2006).
Examination of F-actin with phalloidin (red hue) and nuclei with Hoechst staining (blue hue) on the hAMSC grown on the fibrin-based scaffold
(Differentiated cells; N,O,P) or not (Control cells; H,I,L,M) with NO at 1, 4, 7 and 14 days of culture (O.M. 2006).
doi:10.1371/journal.pone.0034284.g005
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natural and synthetic materials is very attractive and seems
effective [48–50]. The skeleton of the synthetic polymers defines
the gross shape and size of the engineered tissue and supports the
forming tissue during the initial stages, whereas the fibrin gel
facilitates cell invasion and growth. However, major drawbacks of
biodegradable polyester used up to now (such as PGA, PLA, PHB
and their co-polymers) include their inherent hydrophobicity and
rigidity before implantation, lack of natural adhesive proteins and
specific ligands, and the difficulty encountered in the process of
creating balance between the matrix degradation time and the
reconstruction of a new matrix [51].
A special concern is the stiffness of these materials which restrict
their use for cardiac applications where, on the contrary, it is
necessary to have synthetic polymers with high flexibility and
elasticity.
Towards this end, our approach focused on the development of
an elastic scaffold composed of a fibrin layer and a microporous
synthetic layer made of a slowly biodegradable material, such as
the PEtU-PDMS (Fig. 1). The combined scaffold was manufac-
tured in the form of a flat membrane by a spray, phase-inversion
technique in an original way, depositing simultaneously the PEtU-
PDMS material and a thrombin solution over a rotating mandrel
[52]. Afterwards, the thrombin incorporated in the deposited
material reacts with fibrinogen to form a nanostructured fibrin
layer firmly attached on the top of the synthetic layer, as previously
demonstrated by peel-out test [22]. The s-IPN PEtU-PDMS/
fibrin combined scaffold can be tailored with elastic modulus and
mechanical strength matching approximately those of the human
myocardium at the end of diastole [22]; it is biocompatible and
evokes a limited inflammatory response, as already demonstrated
by in vitro and in vivo experiments [21,22,53,54].
Regarding stem cell to be used to reconstitute a damaged heart,
recently an increasing number of scientific papers highlight that
MSCs may secrete a large amount of angiogenic, antiapoptotic,
and mitogenic factors (trophic factors) that are able to improve
cardiac function and reduce scar formation when transplanted in
animal models of MI [55–58]. However, in spite of the above-
mentioned properties, MSCs therapeutic potential for cardiac
repairing is limited by age, disease states of patients and also by the
low cardiac lineage commitment. An important goal of cardiac cell
therapy is the identification of multipotent cells transplantable in
allogenic contexts, and committable through cardiac and vascular
lineages. In this context hAMSCs represent a more suitable source
that could be used in cardiac regenerative medicine. Regarding
the use of NO to stimulate cell cardiac commitment, it has been
shown that NO is a free radical signaling molecule that regulates
several differentiation processes including cardiomyogenesis
[59,60,61]. The treatment of embryonic stem cells with NO
donors such as S-nitroso-N-acetyl-D,L-penicillamine (SNAP) or 2-
(N,N-diethylamino)-diazenolate-2-oxide (DEA/NO), or the trans-
duction with the iNOS gene increases both the number of
spontaneously contracting cell clusters and the expression of
cardiac myosin light chain (MLC) protein, an effect blocked by
NOS inhibitors [59].
The first approach for the selection of a suitable scaffold for
tissue engineering should be the evaluation of its in vitro cell culture
biocompatibility as well as its cytotoxicity [20,21,53,54]. We found
no evidence of cellular toxicity, but on the contrary the results of
our study confirmed the biocompatibility and cell-friendly
property of this scaffold. In particular hAMSCs showed a constant
and steady cellular growth and a higher metabolic activity when
cultured on fibrin combined scaffold (Fig. 3 A, B). Following NO
treatment differentiated hAMSCs cultured on fibrin combined
scaffold showed a longer lasting exponential phase, suggesting
Figure 6. Densitogram analysis. Quantification of vimentin fluorescence intensity, by Imagej Software, showed a decrease in vimentin protein
expression in the hAMSCs treated with nitric oxide (NO) compared to the control cells (CTR). Statistical evaluation of experimental data was
performed with Student’s t-test with P,0.05 as the minimum level of significance.
doi:10.1371/journal.pone.0034284.g006
A Combined Scaffold for Regenerative Medicine
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34284cardiomyogenic commitment and after that a restart of their
proliferation (Fig. 3B). The nanostructured fibrin network (Fig. 2)
on top of the scaffold provides a fine tridimensional matrix that
accordingly enables a tridimensional cell growth. The fibrin
network allows hAMSCs cytoskeleton reorganization (Fig. 5
N,O,P), a decrease of the vimentin mesenchymal staminality
marker expression (Fig. 5) and, at 4 days of NO treatment, the
beginning of cardiomyogenic commitment (Fig. 4).
We also demonstrated that hAMSCs showing a vascular
lineage, when grown on a s-IPN PEtU-PDMS/fibrin combined
scaffold, increase the expression of early and late cardiac
differentiation markers if treated with NO agent. In hAMSCs
the cardiac differentiation marker expression obtained as a long-
lasting response was suggested by the persistence of markers (up to
14 days) even after NO removal. We reported a statistical
significant increase in the expression of cardiac Troponin I and
Nkx2.5 (Fig. 4 A, B) genes and at the same time a statistical
significant decrease in the expression of vascular VEGF and KDR
genes which is time-dependent on s-IPN PEtU-PDMS/fibrin
combined scaffold (Fig. 4 C, D), this result is in accordance to
previous study that demonstrated that physical properties of
polymer scaffold can direct stem cells differentiation to cardio-
myogenic lineage [62]. Interestingly, in the early phase of the NO
treatment, these cells also showed a high expression of vascular
markers (at day 3) that gradually decreased and highlighted, in the
middle phase (days 4–7), a good level of both cardiac and vascular
gene expressions suggesting their use for cardiac engrafting.
A dynamic remodeling of actin filaments and a decrease in the
vimentin protein expression was also reported during NO
treatment (Fig. 5 and 6). The cytoskeleton structure plays a
fundamental role in the cell survival, migration, division and
differentiation process for different cell types [63,64], and also in
the differentiation of mesenchymal stem cells [65,66].
In our study hAMSCs undergo actin cytoskeletal changes
during cardiomyogenic commitment. Control hAMSCs show
more stress fibers with a thinner actin network distributed
throughout the cytoplasm and as cardiac differentiation progresses
they are replaced by some thick actin fibers principally sited in the
region of the cell membrane, a typical characteristic of
cardiomyocyte cells. In particular, after only 4 days of NO
exposure the actin cytoskeleton rearranges and forms large
bundles that run along the longer axis (the periphery of the cell)
where they are more abundant and concentrated (Fig. 5 N,O,P)
compared to the actin network of the undifferentiated cells (Fig. 5
H,I,L,M). Cardiac cells are subjected to mechanical strains and
deformations without loss of shape or stability thanks to an elastic
and compliant cytoskeleton - for this goal a thin and dense actin
network is ideally adequate, as suggested by numerous theoretical
models [67–70]. A drastic change in mechanical properties is due
to the specific functions performed by cardiac cells, so the actin
cytoskeletal reorganization acquired by the hAMSCs is also an
important factor that suggests the achievement of a cardiomyo-
genic commitment.
Vimentin protein, a marker of mesenchymal staminality, is
often expressed at a high level in undifferentiated stem cells where
it regulates cell growth and differentiation [71]. hAMSCs treated
with NO show a decreased vimentin protein expression (Fig. 5
E,F,G) compared to control cells, while the mRNAs of cardiac
differentiation markers increase.
The results of this study confirm the cardiomyogenic commit-
ment effect of the NO treatment on hAMSCs grown on the s-IPN
PEtU-PDMS/fibrin combined scaffold.
In order to evaluate cardiomyocytes-derived hAMSCs capabil-
ity to synchronously contract on s-IPN PEtU-PDMS/fibrin
combined scaffold, we are going to develop an in vitro tool, similar
to the one described by Katare et al. [71], able to apply a
mechanical stretching to the engineered scaffold.
In conclusion we demonstrated that hAMSCs showing a
vascular lineage, when grown on the fibrin side of a cell-friendly
s-IPN PEtU-PDMS/fibrin combined scaffold and treated with
NO, increase the expression of early and late cardiac differenti-
ation markers, and therefore may represents a new cell delivery
system that could be effectively used in cardiac regenerative
medicine.
Furthermore, we can speculate that using this PEtU-PDMS/
fibrin combined scaffold as a cell delivery system, the cells would
be provided with a firm, but also flexible and elastic support,
allowing direct application over the infarcted areas without cell
loss, and providing a more site-directed repair action. Scaffold
components maybe designed in a way that an engraftment may be
expected in the cardiac tissue while the scaffold slowly degrades
over time.
Materials and Methods
Fabrication of fibrin-based scaffold
The medical-grade, aromatic poly(ether)urethane (PEtU) was
purchased from Lubrizol Advanced Materials, Inc. Cleveland,
OH, USA (EstaneH 5714) and the diacetoxy silyl terminated
(tetraacetoxy functional) polydimethylsiloxane (PDMS) from
United Chemical Technologies, Inc. Bristol, PA, USA. The s-
IPN PEtU-PDMS containing 30% of PDMS was synthesized
according to a previously described protocol [21].
Fibrinogen and thrombin were purified from human plasma by
the supplier (KEDRION S.p.A., Castelvecchio Pascoli, Lucca,
Italy). Lyophilized fibrinogen was dissolved in 1% L-Arginine, 1%
L-Lysine and 0,94 PEU/ml aprotinin to obtain a 60 mg/ml
solution (pH between 6.5 and 7.5). Lyophilized thrombin was
reconstituted with a 275 mM CaCl2 in H2Od at a 1250 U/ml
concentration (pH between 6.5 and 8.0).
The s-IPN PEtU-PDMS/fibrin combined scaffold was manu-
factured in the form of a flat membrane by a previously described
spray, phase-inversion technique [22] in a Class 100 clean room.
Briefly, the manufacturing process consisted of two phases: in the
first phase, a 2.5% s-IPN PEtU-PDMS solution and H2Od were
employed; in the second phase, a 1% s-IPN PEtU-PDMS solution
and a 25 U/ml thrombin solution were sprayed simultaneously.
The thrombin-entrapped s-IPN PEtU-PDMS scaffold was
punched to obtain round samples of 1 cm
2 area and placed into
the bottom of a 24-well culture plate. Finally, a fibrinogen solution
(20 mg/ml) was added to each well (600 ml/well). Complete
polymerization reaction into fibrin was achieved after an overnight
incubation at 37uC. The round samples were stored in
physiological saline solution at 4uC and used for the experiments
within 1 week. Sterile conditions were maintained throughout all
steps of the fibrin-based scaffold fabrication.
The sterility of the s-IPN PEtU-PDMS/fibrin combined scaffold
was assessed incubating scaffold samples in Mueller–Hinton broth
(Oxoid S.p.A., Milano, Italy) under agitation at 37uC for 5 days.
No clouding of the broth was observed indicating the absence of
bacterial contamination.
Light microscopy
The s-IPN PEtU-PDMS/fibrin combined scaffold was stained
with Ponceau red dye and observed by a stereo-microscope
(SZH10 microscope, Olympus Optical Co., Tokyo, Japan) to
verify the presence of a homogenous fibrin coating. In brief,
samples were dipped in a staining solution (0.5% w/v in 1% acetic
A Combined Scaffold for Regenerative Medicine
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water to remove the excess dye. Moreover, cross-sectional images
acquired at 606 original magnification were analyzed using
Axiovision Rel 4.6 image analysis software (Carl Zeiss, Jena,
Germany) to measure fibrin and PEtU-PDMS layers thickness of
the fibrin-based scaffold; six random measurements were per-
formed for each image.
Scanning electron microscopy
The structure of the fibrin side of the s-IPN PEtU-PDMS/fibrin
combined scaffold was observed using a scanning electron
microscope (SEM, Jeol 5600, Jeol Italia, Milan, Italy) after gold-
palladium metallization by a sputter coater system (Sputter coater
S150B, Edwards, Irvine, CA, USA). SEM microphotographs were
taken at 10006 and 20.0006 magnifications with a 18–20 kV
acceleration voltage. The images acquired at 20.0006 were
analyzed by the computerized image analysis system (Axiovision
Rel 4.6, Carl Zeiss, Jena, Germany) to quantitatively determine
fibrin fibers mean diameter; six random measurements were
performed for each image.
Stem cell culture
According to the guidelines of the Ethical Committee of the
FBF S. Peter Hospital, hAMSCs were obtained from human term
placenta from healthy women with written informed consent and
generally processed immediately. Isolations are usually performed
with term amnion dissected from the deflected part of the fetal
membranes to minimize the presence of maternal cells. Homog-
enous hAMSC populations can be obtained by a two-step
procedure: pieces of amniotic membrane were minced and treated
for 15 min with 0.25% trypsin-EDTA solution to remove human
amniotic epithelial cells (hAEC), then the supernatant was
discarded and the remaining mesenchymal cells underwent a
second digestion with 0.25% trypsin-EDTA, 10 U/ml DNAse I
(Sigma-Aldrich, St. Louis, USA) and 0.1% collagenase IV (Sigma-
Aldrich) solution in Dulbecco’s modified Eagle’s medium
(DMEM) [72]. The supernatant was transferred to a fresh tube,
neutralized with Fetal Bovine Serum (FBS) then spun at 1500 rpm
for 10 min. Each pellet was re-suspended in 5 ml of culture
medium containing: DMEM, 10% FBS, penicillin (100 U/ml) and
streptomycin (100 mg/ml) (PBI international Milano, Italy), EGF
(10 ng/ml, ImmunoTools, Friesoythe, Germany) and b-mercap-
toetanolo (55 mM, Sigma-Aldrich). The yield from term amnion is
about 1 million of hAMSCs per gram of tissue [72]. hAMSCs were
cultured on plastic Petri dishes at 37uC in a humidified
atmosphere containing 5% CO2. Non-adherent cells were
removed after 1 week and when the culture reached 90%
confluence, cells were recovered using 0.25% Trypsin-EDTA and
plated in Petri dishes at a density of 1610
4 cells/cm
2; the medium
was subsequently changed every 3 days.
Cell characterization by flow cytometry revealed the presence of
mesenchymal markers (CD73, CD105, CD29, CD44, CD54,
ImmunoTools) and the absence of hematopoietic markers (CD34,
CD31, CD45, ImmunoTools) on hAMSC membrane. The
immunophenotypical profile of hAMSC corresponded to the one
reported in literature for bone marrow MSCs [73,74].
At passage 3, 5610
4 stem cells were seeded on the s-IPN PEtU-
PDMS/fibrin combined scaffold and in plastic Petri dishes for cell
metabolic activity and proliferation assays. hAMSCs were exposed
to nitric oxide (NO) or non-exposed to NO (control) and
maintained in culture for up to 14 days in a humidified incubator
(37uC, 5% CO2). The cells were exposed to NO by exogenous
supplementation of S-nitroso-N-acetylpenicillamine (SNAP,
0.4 mM, Invitrogen) at the starting time of the experiment,
replaced on day 2 and maintained until day 4 [59]. Then, cell
cultures were maintained in medium without NO agent, and
replaced with fresh medium every 2 days, until 14 days. These cells
can be kept until passages 5–10.
WST-1 assay
Quantification of hAMSCs metabolic activity was performed by
a colorimetric assay based on the reduction of water-soluble
tetrazolium salts (Cell Proliferation Reagent WST-1; Roche
Diagnostics, Basel, Switzerland).
Exponentially growing hAMSCs were seeded on the s-IPN
PEtU-PDMS/fibrin combined scaffold and in plastic Petri dishes
at a density of 5610
4 cells/scaffold and 5610
4 cells/Petri dish and
cultured for up to 14 days in a humidified incubator (37uC, 5%
CO2). Cells were differentiated by exogenous supplementation of
S-nitroso-N-acetylpenicillamine (SNAP, 0.4 mM). WST-1 reagent
diluted to 1:10 was added in the medium of hAMSCs at 1, 2, 3, 5,
6, 10 and 14 days following plating, and after an incubation of 2 h
in a humidified atmosphere, the supernatants (100 ml) of hAMSCs
were put in 96-well plates and analyzed by means of the formazan
dye. Quantification of the formazan dye produced was performed
by absorbance measurement at 450 nm with a scanning multiwell
spectrophotometer (Biotrack II; Amersham Biosciences, Little
Chalfont, UK).
Bromodeoxyuridine incorporation assay
Exponentially growing hAMSCs were seeded on the s-IPN
PEtU-PDMS/fibrin combined scaffold and in plastic Petri dish at
a density of 5610
4cells/scaffold and 5610
4 cells/Petri and
cultured for up to 14 days. Stem cells were treated or not treated
with SNAP to induce cardiac differentiation. 10 mM BrdU was
added in the medium of hAMSCs at 1, 2, 3, 5, 6, 10 and 14 days
after plating and maintained for 18 h in culture. Cells were then
fixed and incubated for 30 min at 37uC with the anti-BrdU
antibody (1:100; Cell Proliferation Kit; Roche Diagnostics). After
incubation with 2,20-Azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid) for 30 min, the absorbance of 100 ml of supernatant was
measured in an ELISA reader at 450 nm.
Real-time quantitative reverse transcriptase polymerase
chain reaction analysis
Total RNA was extracted at 4,7, 9 and 14 days from control
and SNAP treated hAMSC grown up on the s-IPN PEtU-PDMS/
fibrin combined scaffold, using TRIzol Reagent (Invitrogen). An
average 1–5 mg total RNA per scaffold of cultured cells was
obtained. One microgram of total RNA was used to synthesize
firststrand cDNA with random primers, using 100 U of ImProm-
IITM RT–PCR kit (Promega, Madison, WI, USA). The
quantification of all gene transcripts was carried out by real-time
quantitative reverse transcriptase polymerase chain reaction (RT–
PCR). Experiments were conducted to contrast relative levels of
each transcript and endogenous control GAPDH in every sample.
Gene expression was presented using the (2
2DCt) method,
described by Livak and Schmittgen [75], where DCt=(average
target Ct- average GAPDH Ct). We performed a validation
experiment to prove that the amplification efficiency on target
genes and reference GAPDH was equal. RT-PCR was performed
with Sybr Green I Mastermix, using an ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA). Each reaction was run in triplicate and contained 0.5–1 mL
of cDNA template along with 250 nM primers in a final reaction
volume of 25 mL. The genes investigated were NK2 transcription
factor related, locus 5 (nkx2.5) and cardiac troponin I (TnI) for
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tiation. The annealing temperatures for all primers used in this
study are 60uC and the sequences are:
kx2.5: 59-CAGCGACCCCGACCCAG-39;5 9-
GCTTCCTCCGCCGTCGC-39,
TnI: 59-GGACAAGGTGGATGAAGAGA-39;5 9-
AGGGTGGGCCGCTTAAACT-39,
VEGF: 59-CTTGGGTGCATTGGAGCCT-39;5 9-
CTGCGCTGATAGACATCCAT-39,
KDR: 59-CAGCATCACCAGTAGCCAG-39;5 9-TTATACA-
GATCTTCAGGAGCTT-39,
GAPDH: 59-CATCATCTCTGCCCCCTCT-39;5 9-
CAAAGTTGTCATGGATGACCT-39
Cycling parameters were: 50uC for 2 min, 95uC for 10 min (to
activate DNA polymerase), then 40–45 cycles at 95uC for 15 s and
60uC for 1 min. Melting curves were performed using Dissociation
Curves software (Applied Biosystems) to ensure that only a single
product had been amplified. As negative controls, reactions were
prepared in which RNA or reverse transcriptase had previously
been omitted during reverse transcription.
Immunofluorescence analysis
hAMSCs were seeded on the s-IPN PEtU-PDMS/fibrin
combined scaffold at a density of 5610
4 cells per scaffold and
cultured for 14 days, in absence (CTR) or in presence (NO) of
differentiating agent, as shown in the above protocol. At 1, 4, 7
and 14 days, hAMSCs were fixed in paraformaldehyde 4% at 4uC
for 10 min, washed twice in Ca
2+/Mg
2+-free PBS and permea-
bilized at room temperature for 15 min (0.1% Triton X-100, 1%
BSA; Sigma-Aldrich). hAMSCs were incubated with phalloidin
TRIC (tetrametyl rhodamine isothiocyanate) conjugated (1:100),
an anti-actin toxin (Sigma-Aldrich), in a blocking buffer for 1 hour
or with primary antibody Vimentin (1:200) (abcam, Cambridge,
UK). After washing in PBS containing 0.1% Triton X-100 and 1%
BSA, the cells were incubated with the anti-mouse secondary
antibody (1:100) (Chemicon, Billerica, MA, USA). Cells were
washed three times with PBS, stained for nuclei localization with
Hoechst 33342 (trihydrochloride-trihydrate) and examined. The
scaffolds were overturned on cover glasses and tested by indirect
immunofluorescence for the presence of vimentin and actin
filaments. Fluorescence measurements were obtained using an
inverted microscope (Olympus IX51, RT Slider SPOT -
Diagnostic instruments, Sterling Heights, MI, USA) equipped
with a 206 objective and with a cooled CCD camera (Spot RT
Slider, acquisition rate five frames per second, full frame;
Diagnostic Instruments, Sterling Heights, MI, USA). No signifi-
cant fluorescent signal was detectable with the secondary antibody
alone. Densitometric analysis of the vimentin immunofluorescence
was performed with Imagej Software.
Statistical analysis
Statistical analysis of the data was performed using Student’s t-
test, with P#0.05 as the minimum level of significance. For WST-
1 and Bromodeoxyuridine incorporation assays the results were
obtained by six independent experiments (n=6), while for the
values obtained by RT-PCR analysis each bar represents the 6SD
of three independent experiments (n=3). Data are shown as mean
6 standard deviation (SD).
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